HomeCompareEGIEY vs ABBV

EGIEY vs ABBV: Dividend Comparison 2026

EGIEY yields 4.27% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 EGIEY wins by $800.2K in total portfolio value· pulled ahead in Year 3
10 years
EGIEY
EGIEY
● Live price
4.27%
Share price
$6.55
Annual div
$0.28
5Y div CAGR
54.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$902.6K
Annual income
$569,021.89
Full EGIEY calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — EGIEY vs ABBV

📍 EGIEY pulled ahead of the other in Year 3

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodEGIEYABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, EGIEY + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
EGIEY pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

EGIEY
Annual income on $10K today (after 15% tax)
$363.36/yr
After 10yr DRIP, annual income (after tax)
$483,668.61/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, EGIEY beats the other by $462,612.60/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of EGIEY + ABBV for your $10,000?

EGIEY: 50%ABBV: 50%
100% ABBV50/50100% EGIEY
Portfolio after 10yr
$502.4K
Annual income
$296,896.82/yr
Blended yield
59.09%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

EGIEY
No analyst data
Altman Z
1.1
Piotroski
6/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

EGIEY buys
0
ABBV buys
0
No recent congressional trades found for EGIEY or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricEGIEYABBV
Forward yield4.27%3.06%
Annual dividend / share$0.28$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR54.7%40.6%
Portfolio after 10y$902.6K$102.3K
Annual income after 10y$569,021.89$24,771.77
Total dividends collected$846.8K$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: EGIEY vs ABBV ($10,000, DRIP)

YearEGIEY PortfolioEGIEY Income/yrABBV PortfolioABBV Income/yrGap
1$11,361$661.31$11,550$430.00$189.00ABBV
2$13,243$1,086.28$13,472$627.96$229.00ABBV
3← crossover$16,001$1,830.64$15,906$926.08+$95.00EGIEY
4$20,318$3,197.87$19,071$1,382.55+$1.2KEGIEY
5$27,612$5,871.15$23,302$2,095.81+$4.3KEGIEY
6$41,080$11,535.48$29,150$3,237.93+$11.9KEGIEY
7$68,769$24,812.97$37,536$5,121.41+$31.2KEGIEY
8$133,637$60,054.29$50,079$8,338.38+$83.6KEGIEY
9$311,719$168,727.42$69,753$14,065.80+$242.0KEGIEY
10$902,561$569,021.89$102,337$24,771.77+$800.2KEGIEY

EGIEY vs ABBV: Complete Analysis 2026

EGIEYStock

Engie Brasil Energia S.A., together with its subsidiaries, generates, sells, and trades in electrical energy in Brazil. The company operates 68 plants, including 11 hydroelectric power plants; 4 thermal power plants; 49 wind-powered plants; 3 biomass; 2 photovoltaic solar power plant; 1 conventional thermoelectric plant; and 2 small hydroelectric plants in the 21 states of Brazil. As of December 31, 2021, it had an installed capacity of 8,218.7 megawatts. The company also transports natural gas through 4,500 km of gas pipelines in the Southeast, Northeast, and North regions of Brazil. In addition, it engages in manufacture, wholesale, retail sale, operation, and maintenance of solar panels. The company was formerly known as Tractebel Energia S.A. and changed its name to Engie Brasil Energia S.A. in July 2016. The company was incorporated in 2005 and is headquartered in Florianópolis, Brazil. Engie Brasil Energia S.A. operates as a subsidiary of ENGIE Brasil Participações Ltda.

Full EGIEY Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this EGIEY vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

EGIEY vs SCHDEGIEY vs JEPIEGIEY vs OEGIEY vs KOEGIEY vs MAINEGIEY vs JNJEGIEY vs MRKEGIEY vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.